chrisvoncsefalvay/vaers-outcomes huggingface dataset:
Soreness; This spontaneous case was reported by a consumer and describes the occurrence of PAIN (Soreness) in a 46-year-old male patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch nos. 040B21A and 006B21A) for COVID-19 vaccination.     No medical history was provided by the reporter.  Concomitant products included FAMOTIDINE for Gastric pH decreased, MELOXICAM for Pain, SILDENAFIL for an unknown indication.   On 19-Mar-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 16-Apr-2021, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) dosage was changed to 1 dosage form. On 16-Apr-2021,  after starting mRNA-1273 (Moderna COVID-19 Vaccine), the patient experienced PAIN (Soreness). At the time of the report, PAIN (Soreness) outcome was unknown. Not Provided          The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was not applicable  No treatment reported   This case was linked to MOD-2021-080291, MOD21-078355 (E2B Linked Report). This case was linked to MOD-2021-080337; Sender's Comments:  MOD-2021-080291:1st dose MOD21-078355:Fiance's case
Pt woke up @ 3AM on 11DEC, felt very hot mom gave APAP; About 9AM on 11DEC pt told mom arms, legs, feet felt numb, hard for pt to walk, shakey; Pt told mom leg is broken; t103.8;
Large red patch on my upper left arm. Slightly raised. Warm to the touch. Sensitive to the touch. A tiny bit itchy.
Rash at injection site started 1 1/2 weeks post injection. Has grown significantly after 1 day.
Had chills at 3 am, took Tylenol 750 mg PO. Skipped work that day due to unexpected chills. Had a fever of 100.3 F, neck pain, headache and muscle aches around noon the same day. Took another Tylenol 750 mg. At 9:00 PM and next morning at 6:00 AM took Tylenol 750 PO. No more symptoms observed.
elevated temperature of 99.3, some shivering  soreness through upper back, shoulders, and neck with a bit of stiffness  all mild
his fingers started having a tingling sensation; This is a spontaneous report received from a contactable consumer (patient). A male patient of unspecified age received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Solution for injection and lot number: UNKNOWN) via an unspecified route of administration on 15Apr2021 as a single dose for COVID-19 immunization. Medical history and concomitant medications were not reported. The patient previously received the first dose of the BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE, Solution for injection and lot number: UNKNOWN) via an unspecified route of administration on an unspecified date as a single dose for COVID-19 immunization. On 15Apr2021, half hour after the vaccine patient fingers started having a tingling sensation that had continued. The outcome of the event was not recovered.  No follow-up attempts are needed; information about lot/batch number cannot be obtained.
Patient who received Moderna COVID -19 vaccine  and was unexpectedly found deceased in his sleep early around 2 AM on October 30, 2022.  Patient recently underwent cardiac stress test before a month or two which was normal. Strongly suspect unexpected death of patient is directly associated with Moderna COVID -19 vaccination.
11/10/2009 thrombocytopenia/ ITP, patient presented on 11/10/2009 with Petechiae on face, chest, arms, and legs. Purpura on leg.
FAINTING; This spontaneous report received from a pharmacist via a company representative concerned a patient of unspecified age and sex. The patient's weight, height, and medical history were not reported. The patient received covid-19 vaccine ad26.cov2.s (suspension for injection, route of administration not reported, batch number: Unknown) frequency 1 total, dose was not reported, administered on 11-APR-2021 for prophylactic vaccination. The batch number was not reported. The Company is unable to perform follow-up to request batch/lot numbers. No concomitant medications were reported.  On 11-APR-2021, the patient experienced fainting after the vaccine was administered. The action taken with covid-19 vaccine ad26.cov2.s was not applicable. The outcome of fainting was not reported. This report was serious (Other Medically Important Condition).; Sender's Comments: V0: 20210420923-COVID-19 VACCINE AD26.COV2.S-fainting. This event is considered unassessable. The event has a compatible/suggestive temporal relationship, is unlabeled, and has unknown scientific plausibility. There is no information on any other factors potentially associated with the event.
Abdominal pain Narrative:  Noted abdominal pain the day after the 2nd dose - described as getting "punched in the gut", and relieved by lying in the fetal position. Lasted x 7 hours. No nausea/vomiting/diarrhea. Missed work x 1 day. No known prior COVID infection.  Other Relevant History:
Soreness at injection site, red/raised bumps at injection site; fever; severe headaches. Headaches continue.
Covid-19 Lot # FE3590 Vial PAA165969 Exp 2/22 was placed in the freezer after we received it. It should have been pulled out of the freezer on 10/19/21 at 12:00PM according to the storage guidelines and placed in the refrigerator for 31 days.  Our staff did not pull the vial out of the freezer on this date. The staff noticed the date this morning, November 2, 2021 at 0830.  There were 22 patients who received the COVID vaccination during this time frame. The vials were pulled out of the freezer, thawed, and diluted per instructions during 10/19/21 through November 1, 2021. There are 27 vials that were not used and have been set aside to waste.
I devolved a rash around the let side of my rib cage along with some tingling, shooting pains. I suspected that I had shingles so I went to Urgent Care. They confirmed that I did have shingles. I was on an anti viral medication of famciclovir 500mg 3xday for 7 days. For 2 weeks I had itching, sensitivity, and a stinging pain in my left rib cage. I also had fatigue and light nausea for first couple of days. All of those symptoms gradually went away.
At 6pm on 1/25/21, 10 hours after dose 2 of the Covid vaccine she began to shake, have chills . She did not take her temperature but felt she had a fever. She went to sleep and woke at 4am and had wet the bed. The next day, 1/26/21 she had a headache, tremors and chills. She stayed home from work. On 1/27/21 she went to work, felt better except for a headache.  On 1/28/21 she went to work but felt "weird". At 12:30 that day her head was pounding, glassy eyed, felt chest pressure and was "foggy". She went to eat lunch but on the way back to the elevator her legs buckled and she could not walk. She was escorted by wheelchair to her desk . Her Manager stated she did not look well and 911 was called. She was taken to an adult ED. She was thoroughly evaluated ( Head CT, blood work, EKG ) give IV fluids. She was found to have a UTI and was placed on Keflex. Given RX for nausea and vomiting. She was discharged home to follow up with PCP. 1/29/21, she is feeling better except for some fatigue.
Migraines; Nausea; Fever; Chills; Aches; This is a spontaneous report from a non-contactable consumer, the patient. A 16-year-old male patient received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: UNKNOWN) via an unspecified route of administration in the left arm on an unknown date in May2021 (at the age of 16-years-old) as a single dose for COVID-19 immunisation. The patient had no medical history and no known allergies. Prior to the vaccination, the patient was not diagnosed with COVID-19. Concomitant medications were not reported. The patient previously received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: UNKNOWN) via an unspecified route of administration on an unknown date as a single dose for COVID-19 immunisation. The patient did not receive any other vaccines within four weeks prior to the vaccination. On 07May2021, the patient experienced migraines, nausea, fever, chills and aches. The event resulted in doctor or other healthcare professional office/clinic visit. Since the vaccination, the patient had not been tested for COVID-19. The clinical outcome of the event migraines, nausea, fever, chills and aches were resolving at the time of this report.   No follow-up attempts are possible; information about lot/batch number cannot be obtained. No further information is expected.
This spontaneous report as received from a registered pharmacist refers to a patient of unknown age. On 04-MAR-2013 the patient was vaccinated with ZOSTAVAX (lot # reported as J000433, Exp. Date: 10-APR-2014) exposed to 68 F for 66 hours. The pharmacist also reported that patient obtained this ZOSTAVAX in question and transported it to the physician's office for administration, no further temperature details are available during this transport time. No adverse symptoms reported. Additional information has been requested.
Received flu shot on 10-15-14 at 830 am. Around 300 pm began double vision in periphery (R) eye. Vision worsened next day. Saw ophthalmologist on 10-17-14. Dx vascular event. On 10-18-14 vision worsened. Went to ER. CT scan WNL. Double vision cont x 2 wks. At this time vision still not perfect.
Confusion, disorientation; patient was getting ready to leave her home but did not know what day is is or where she was going. Also reports feeling tired and having chills. Noted to have hypoxia here in ER.
Looked pale and no energy on day 4 after vaxx. Day 5 had stroke between 0700-1100. Thought he was sick with flu. Did not recover after Day 8 and called primary doctor.
COVID-19; COVID-19; This is a spontaneous report received from contactable reporter(s) (Nurse). The reporter is the patient.  A 56-year-old female patient (not pregnant) received BNT162b2 (BNT162B2), on 14Jan2021 at 16:30 as dose 1, single (Lot number: 026L20A), in left arm, on 15Feb2021 as dose 2, single (Lot number: 026L20A), in left arm and on 26Oct2021 as dose 3 (booster), single (Lot number: 076C21A) at the age of 55 years, in left arm for covid-19 immunization. The patient's relevant medical history included: "Hashimoto" (unspecified if ongoing). The patient took concomitant medications, also reported as other medication in two weeks. Past drug history included: Ceclor, reaction(s): "Known allergies : Celcor". The following information was reported: VACCINATION FAILURE (medically significant), COVID-19 (medically significant) all with onset 2022, outcome "not recovered" and all described as "COVID-19". The patient underwent the following laboratory tests and procedures: SARS-CoV-2 test: Positive. Therapeutic measures were taken as a result of vaccination failure, covid-19 included Paxlovid started on 08Jun2022 and stopped on 12Jun2022. Clinical course was reported as Took Paxlovid for 5 days, mild symptoms Covid. Fast recovery. Chest heaviness residual. Rebound Covid Positive 2.5 weeks later, mild symptoms (reported as on 25Jun2022). Notified Doctor. Patient received no treatment for symptoms and not recovering from symptoms.; Sender's Comments: The vaccine efficacy varies from one patient to another and can be affected by different factors; however, a contributory role of the suspect vaccine BNT162B2 to the Vaccination failure (LOE) and COVID-19 cannot be ruled out.
Information has been received from a female consumer who is a registered nurse who a few years ago when it first came out was vaccinated with a dose of hep b vaccine recombinant. Subsequently a few weeks later, she started experiencing shooting pains to the temporal area. A few days later that pt was administered a dose of hep b vaccine recombinant. It was reported that the pains continued and a CT scan was done with negative results. The pt was treated wtih Dilantin for 1 to 1 1/2 yers until the symptoms resolved. It was reported that the pt had no further symptoms. Additional info has been requested.
This spontaneous report as received from a registered nurse refers to an unspecified number of patients of unknown ages and genders. The patients' medical history was not reported. On unknown dates, the patients were vaccinated with  improperly stored doses of VAQTA (route and dosage unknown;lot # M002268 EXP 20-SEP-2017). No adverse event was reported. This is one of several reports received from the same reporter. Additional information has been requested.
Information has been received from a health professional concerning a patient who was vaccinated with a second dose of rotavirus G1 G2 G3 G4 P1 reassortant vaccine (human-bovine) two days earlier than recommended, two days before four weeks.  No product quality complaint was involved.  Additional information has been requested.
Each 45 day, when she falls asleep, she wakes up with half of her face jumping and she doesn't feel her tongue. It lasts about 30-45 seconds until it stops. After it occurs, her face hurts her.
3 or 4 hour after get the Vaccine, i couldn't breath. and continue with light fever and headache. i took acetaminophen 500mg to reduce the fever and got sleep. the next morning i woke up with diarrhea... i eat plan yogurt to make it stop.  diarrhea stop, but during this 2 days got so much bad headache. i take Tylenol, but it just cover for few hour and the pain comeback.
no aditional AE; patient was administered MMR II intramuscularly in the tight instead of subcutaneously; This spontaneous report was received from a registered nurse and refers to a 12-month-old male patient.  Information regarding the patient's pertinent medical history, concurrent conditions, drugs reactions or allergies were not provided. Concomitant therapies includes varicella virus vaccine live (Oka/Merck) (VARIVAX) and hepatitis A Vaccine, Inactivated (VAQTA).  On 22-MAR-2022, the patient was vaccinated with measles, mumps, and rubella (wistar ra 27-3) virus vaccine, live (M-M-R II), subcutaneous injection, 0.5 milliliter, lot number U013035 has been verified to be valid lot number for measles, mumps, and rubella (wistar ra 27-3) virus vaccine, live (M-M-R II), expiration date: 23-APR-2023, and sterile diluent (MERCK STERILE DILUENT) (lot number, expiry date). However, the vaccine was administered intramuscularly in the right tight instead of subcutaneously (incorrect route of product administration). No adverse event was reported.
Contracted Covid 19. There is a red rash in the area where I received the vaccine.
Extremely painful and loud ear ringing.  I thought my ears were going to bleed.  Extreme rotary vertigo for 24 hours.  Treated with large doses of benedryl to stop the spinning.  Tinnitus ringing is back to regular levels.  I've had tinnitus for 30 years, this vaccine triggered something I have never experienced before.
Patient presented to the ED and was subsequently hospitalized for covid 19 within 6 weeks of receiving covid vaccination.
when stood up suffered from dizzy spells but did not faint. Felt better after drinkning some soda and resting.
The patient received vaccine after improper storage; No other AE; This spontaneous report has been received from an office manager concerning a patient of unknown age and gender. The patient's pertinent medical history, drug reactions/allergies, concurrent condition and concomitant medication were not provided.   It was reported the following vaccines were improperly stored and administered to multiple patients (dates of administration were unknown): varicella virus vaccine live (Oka/Merck) (VARIVAX); Measles, Mumps, and Rubella (Wistar RA 27-3) Virus Vaccine, Live (M-M-R II) and Measles, Mumps, Rubella and Varicella (Oka-Merck) Virus Vaccine Live (PROQUAD) (all strength, dose, frequency, route, lot number and expiration date were not reported) for prophylaxis. The reporter did not know which vaccines the patient received. The reporter also was not sure about the previous temperature excursion details for the vaccines. No other adverse event was reported.    This is one of several reports received from the same reporter.; Sender's Comments:  US-009507513-2108USA003202: US-009507513-2108USA003205: US-009507513-2108USA003207:
MMR 2 given on 03/20/2001. Approximately 3 hours later started to have noticeable bruising. On 05/05/2001 platelet count 25,000.
Patient awoke on December 27th extremely stiff and sore with muscle ache. He went to see Doctor the following week as the problem only got worse.  The doctor treated him for a couple of weeks before referring him to another doctor.
NO adverse event/sx. Pt. was to receive a bivalent vaccine and given monovalent.
sore arm; feeling fatigued; arm was increasingly becoming red and hot/bright red; arm was increasingly becoming red and hot; redness and swelling the size of your hand; This spontaneous case was reported by a consumer and describes the occurrence of ERYTHEMA, SKIN WARM, PERIPHERAL SWELLING, PAIN IN EXTREMITY, and FATIGUE in a 71-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch nos. 001A21A and 032L20A) for COVID-19 vaccination.     The patient's past medical history included Atrial fibrillation. Concomitant products included ELIQUIS, FLECAINIDE, METOPROLOL, ATORVASTATIN, and GABAPENTIN for an unknown indication.   On 27-Jan-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 25-Feb-2021, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) dosage was changed to 1 dosage form. On 26-Feb-2021, the patient experienced ERYTHEMA, SKIN WARM, PERIPHERAL SWELLING, and FATIGUE. On 01-Mar-2021, the patient experienced PAIN IN EXTREMITY. The patient was treated with BENADRYL from 26-Feb-2021 to 27-Feb-2021 at an unspecified dose and frequency. On 26-Feb-2021, FATIGUE outcome was unknown. At the time of the report, ERYTHEMA, SKIN WARM, PERIPHERAL SWELLING, and PAIN IN EXTREMITY outcome was unknown.
This spontaneous report was received from a medical assistant regarding an adult patient of unknown gender. The patient's medical history, concurrent conditions and concomitant medications were not reported. On 04-APR-2018 the patient was vaccinated with pediatric dose of VAQTA 50/1.0 U/ml (lot# and expiration date was not reported), intramuscularly for prophylaxis (incorrect dose administered). No adverse effect was reported.
generalizied non pruritic hives on B/L UE, TRUNK, CHEST, BACK, and LEGS that started the day after the vaccine. He reports he never had any SOB, difficulty breathing, or feeling like his throat was closing. Denied any other s/sx of allergic reaction other than the hives.  He also reports the hives are not itchy.
muscle aches; tingling fingertip; Fever; Moderna COVID-19 booster; Moderna COVID-19 booster; This is a spontaneous report received from a contactable reporter(s) (Consumer or other non HCP). The reporter is the patient.  A 53 year-old male patient received bnt162b2 (BNT162B2), intramuscular, administered in arm left, administration date 04Mar2021 11:30 (Lot number: EL3247) as dose 1, single and intramuscular, administered in arm left, administration date 25Mar2021 10:10 (Lot number: EP6955) as dose 2, single for covid-19 immunisation; covid-19 vaccine mrna (mrna 1273) (MODERNA COVID-19 VACCINE), intramuscular, administered in arm left, administration date 14Nov2021 10:00 (Lot number: 071F21A) as dose 3 (booster), single for immunisation. The patient had no relevant medical history. There were no concomitant medications. The following information was reported: IMMUNISATION (non-serious), INTERCHANGE OF VACCINE PRODUCTS (non-serious) all with onset 14Nov2021 10:00, outcome "unknown" and all described as "Moderna COVID-19 booster"; PYREXIA (non-serious) with onset 14Nov2021 23:00, outcome "recovered" (Nov2021), described as "Fever"; MYALGIA (non-serious) with onset 15Nov2021, outcome "recovered" (Nov2021), described as "muscle aches"; PARAESTHESIA (non-serious) with onset 15Nov2021, outcome "recovered" (15Nov2021), described as "tingling fingertip". Therapeutic measures were not taken as a result of pyrexia, paraesthesia. Therapeutic measures were taken as a result of myalgia. Additional information: The patient received vaccine at pharmacy or drug store. The symptom of tingling fingertips did not occur till the morning of 15Nov2021. The patient received booster dose due to high risk of frequent institutional or occupational exposure to coronavirus (and at risk of serious Covid-19 complications). The patient did not receive any prior vaccinations within 4 weeks and the patient did not have any relevant tests or specific relevant test for thromboembolic events with thrombocytopenia. The patient received treatment with acetaminophen due to event myalgia. It was reported that tingle sensation lasted about 15 minutes. Include and hand and fingertips. Only on right hand. No tingle on left hand or finger. It went away by itself.  Follow-up attempts are completed. No further information is expected.
Partial loss of nerve function in left hand pinky finger, occurred after each of the first two events, but was not cognitively associated with the vaccination event.  The situation is persistent though patient continues to attempt recovery of lost nerve function.  After the 3rd vaccination event, patient observed virtually complete temporary loss of nerve function to the pinky finger of the left hand.  This is the event which caused patient to recognize the link between the vaccine and the loss of nerve function.
Felt like a panic attack. Short of breath, heart racing, tunnel vision, dizzy tingling face/lip. Worst of it lasted about 2-3 hours. Very fatigued afterward.
heart palpitations; chest pressure; mild sore throat; This is a spontaneous report from a contactable consumer reported for a 62-year-old non-pregnant female patient received second dose of bnt162b2 (PFIZER-BIONTECH COVID-19 VACCINE, Formulation: Solution for injection, Batch/lot number: EL9266), via an unspecified route of administration on 16Feb2021 14:00 at single dose in left arm for covid-19 immunization.  The patient's medical history included hypertension and peanuts allergy. Historical vaccine included bnt162b2 on 22Jan2021 (Lot number: EL3247, Administration time: 04:00 PM, vaccine location: Left arm, dose number: 1). Concomitant medications included hydrochlorothiazide, ergocalciferol (VITAMIN D). Past drugs included ACE inhibitors for known allergies, tetracycline for known allergies. On 17Feb2021 at 16:00, the patient experienced heart palpitations, chest pressure and mild sore throat. The patient did not take any treatment for the events. The outcome of the events was not resolved.
she lost full motion on being able to reach and bend down.; she lost full motion on being able to reach and bend down.; She says she has pain and inflammation; She says she has pain and inflammation; This is a spontaneous report from a contactable consumer (patient). A female patient of an unspecified age received BNT162B2 (PFIZER-BIONTECH COVID-19 VACCINE, solution for injection), dose 2 via an unspecified route of administration on 15May2021 16:00 (Batch/Lot number was not reported) as 2nd dose, single dose for COVID-19 immunization. Medical history included some discomfort in her neck/shoulder. Concomitant medication included paracetamol (TYLENOL) taken for an unspecified indication, start date not reported. The patient reported she lost full motion on being able to reach and bend down on 15May2021 at 18:30. She said  she has pain and inflammation. She was pretty sure it was unrelated to the vaccine. The outcome of the events was unknown.  The patient has been taking paracetamol and she wanted to know if she can take Aleve after the vaccination.  Information about lot/batch number has been requested.
Patient came in with a quarter sized lump on his arm where the vaccine was given. He stated that it only caused discomfort when he pressed on it.
I contracted COVID-19 on 07/07/2022 with symptoms of runny nose, sneezing, cough, headache, fatigue, and congestion. I was prescribed Paxlovid on 07/07/2022.  I was ill for 5 days before my symptoms began to resolve. My symptoms returned on 07/19/2022 exactly as my initial illness, with no new or worsening symptoms.